Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.
Insider & Institutional Ownership
8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Cardio Diagnostics and Black Diamond Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
| Black Diamond Therapeutics | N/A | -32.10% | -25.21% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardio Diagnostics | $10,000.00 | 541.68 | -$6.50 million | ($2.92) | -0.63 |
| Black Diamond Therapeutics | $70.00 million | 1.72 | $22.37 million | ($0.75) | -2.80 |
Black Diamond Therapeutics has higher revenue and earnings than Cardio Diagnostics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Cardio Diagnostics and Black Diamond Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| Black Diamond Therapeutics | 1 | 2 | 8 | 0 | 2.64 |
Black Diamond Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 388.10%. Given Black Diamond Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Cardio Diagnostics.
Volatility and Risk
Cardio Diagnostics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 3.31, suggesting that its stock price is 231% more volatile than the S&P 500.
Summary
Black Diamond Therapeutics beats Cardio Diagnostics on 12 of the 14 factors compared between the two stocks.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
